Home/Filings/4/0001104659-22-078787
4//SEC Filing

Altarac David 4

Accession 0001104659-22-078787

CIK 0001724344other

Filed

Jul 10, 8:00 PM ET

Accepted

Jul 11, 4:03 PM ET

Size

12.2 KB

Accession

0001104659-22-078787

Insider Transaction Report

Form 4
Period: 2022-07-07
Altarac David
Chief Medical Officer
Transactions
  • Other

    Stock Option (right to buy)

    2022-07-1192,3070 total
    Exercise: $2.44Common Stock (92,307 underlying)
  • Other

    Stock Option (right to buy)

    2022-07-1150,0000 total
    Exercise: $4.94Common Stock (50,000 underlying)
  • Disposition to Issuer

    Common Stock

    2022-07-11150,0000 total
  • Disposition from Tender

    Common Stock

    2022-07-07$2.20/sh17,572$38,6580 total
Footnotes (3)
  • [F1]Disposed of to Innoviva Merger Sub, Inc. ("Merger Sub"), which, pursuant to the Agreement and Plan of Merger, dated May 23, 2022, by and between the Issuer, Innoviva, Inc. ("Innoviva"), and Merger Sub (the "Merger Agreement"), completed a tender offer to acquire all of the issued and outstanding shares of the Issuer's common stock (other than those shares owned by Innoviva and Merger Sub) at a purchase price of $2.20 per share (the "Offer Price").
  • [F2]Pursuant to the Merger Agreement, each Issuer restricted stock unit ("RSU") that was outstanding immediately prior to the date and time at which the merger of Merger Sub with and into the Issuer (the "Merger") became effective (the "Effective Time") was cancelled and converted into the right to receive a right to receive a number of RSUs in respect of shares of Innoviva common stock equal to (x) the number of Shares subject to Issuer RSUs immediately prior to the Effective Time, multiplied by (y) the Offer Price, divided by (z) the per share volume-weighted average price of Innoviva common stock for the 10 business days prior to the closing date of the Merger.
  • [F3]Pursuant to the Merger Agreement, at the Effective Time, each vested and unvested Issuer stock option with a per share exercise price equal to or greater than the Offer Price was cancelled immediately prior to the Effective Time, with no consideration payable. All stock options held by the reporting person were cancelled in the Merger as the exercise price of each such option was greater than the Offer Price.

Issuer

Entasis Therapeutics Holdings Inc.

CIK 0001724344

Entity typeother

Related Parties

1
  • filerCIK 0001792615

Filing Metadata

Form type
4
Filed
Jul 10, 8:00 PM ET
Accepted
Jul 11, 4:03 PM ET
Size
12.2 KB